Pharma BD Deal Intelligence

Immutep Limited / Cardiff University

2024 · Licensing/Option · Complete

Immutep signed an exclusive license with Cardiff University for development and commercialization rights to a series of next-generation anti-LAG-3 small molecule compounds for cancer, identified through prior collaboration with Cardiff scientists. Financial terms comprise a GBP 25,000 upfront payment, a milestone on first commercial sale and low single-digit sales royalties; the programs are preclinical and aim to provide an oral alternative to antibody-based LAG-3 therapies.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals